• Minicabecera4

News

vexoderm

ArtinVet and Laboratoire Destaing have reached an agreement for the commercialisation of the product Vexoderm with the aim of expanding its use among the veterinarians of France and Belgium.

Vexoderm is an innovative moist healing dressing developed by ArtinVet, successfully marketed in Spain since 2014 and recently in Portugal. Its special and patented design is the result of years of research to achieve an improvement in the skin problems of dogs, cats and horses. Vexoderm offers the advantage of being able to space the cures with a weekly periodicity, leaving the control of the evolution exclusively in the hands of the veterinarian.

One of its most novel aspects is the natural origin of its components, carob in the dressing and curcumin in the hydration solution, both well known in traditional medicine for its excellent properties, among others, the improvement of skin conditions.

Vexoderm comes in two versions, according to its size, 9x4 and 10x7 cm.

About Laboratoire Destaing

Laboratoire Destaing is a French pharmaceutical company specialised in the diagnostic and treatment of allergies for cats, dogs and horses, and also in the diagnostic of human contact dermatitis.

About ArtinVet Innovative Therapies

ArtinVet, focussed on regenerative therapies for veterinary medicine offers innovative products and services to treat skin problems in dogs, cats and horses.


Histocell laboratory

With an investment of 2 million euros, Histocell has started the construction of a production plant in the Basque Country.

After 10 years of research and with several products on the market, Histocell is now working on the creation of a new production plant of its own, in order to obtain greater control of production, quality and costs . Continuing with the commitment to work in the Basque Country, this plant will be raised in Larrabetzu, close to the current facilities located in the Technology Park of Bizkaia.

This factory, with an area of 2000 m 2, will initially host producing Reoxcare, Vexoderm and Histogel lines, products already on the market and with a great international potential.

In addition, this new infrastructure will create 14 new jobs, and will be the starting point for a new stage in the career of Histocell, which after many years of research and investment, now offers a range of maedical devices that seek to improve people’s quality of life, offering a solution to those problems that do not currently have one.

The production will therefore begin with the Reoxcare line, for the treatment of skin and difficult to heal wounds, including its veterinary line Vexoderm.


Histocell laboratory

The Basque biopharmaceutical company, which celebrates its tenth anniversary in the NorayBio Group, strengthens its capital to market their health products and continue clinical phases of their cell drugs.

Last week, Histocell shareholders approved a capital increase of 4 million Euros to face a new stage of growth of the company. This expansion has ushered in two new partners to the company: the IFC Group, a leading Spanish company in the development and commercialisation of cosmeceuticals and dermatology prescription and a French "family office", that becomes the first international shareholder of the company.

The round was led by IFC Group, which becomes the third largest shareholder of the company in number of shares. The addition of IFC to the shareholders and to the administration board occurs after several years of technical collaboration that have yielded excellent results with the addition of new ingredients and products to the commercial portfolio of IFC.

This round of funding was also attended by the main shareholders of Histocell, reinforcing its support and confidence in the evolution and future of the company.

Histocell's current situation, celebrating its 10th anniversry in NorayBio Group, is excellent. After the obtention of the CE mark of its first medical device, Reoxcare, the innovative wound dressing for difficult healing wounds will begin to be marketed in Hong Kong this quarter, thanks to the trade agreement with Chinese company Luqa Pharma. Histocell has recently joined the grant of the patent in the US to those previously obtained to protect Reoxcare in major world markets.

In the area of cell therapy drug development, Histocell faces forward the entry into clinic of its main cell product, HC016. Firstly indicated for the treatment of acute spinal cord injury and develope in collaboration with Ferrer pharmaceutical company in the Neurosave project, it has obtained the authorisation from the Spanish Medicines Agency for the start of Phase I/II in patients from three Spanish hospitals.

"We highly value the incorporation of such an important industrial group as IFC to our shareholders and administration board. It brings us international experience, marketing channels and financial strength.” — Julio Font, CEO of Histocell.

 “After the close cooperation that has united us in the recent years, this was the natural next step as part of the entreprenurial concern we share. Promoting research and providing innovative solutions tailored for physicians and patients is our commitment, and a good example of this is our joining to Histocell” Juan Matji, IFC.


histocell-sala-blanca-1-web

20.07.2016 - Seed Capital Bizkaia (Spanish version)

En apenas una década, la empresa radicada en Bizkaia, ha completado el desarrollo de un variado catálogo de productos sanitarios y de medicamentos de terapia celular en el ámbito de la medicina regenerativa y ha logrado registrar más de 30 patentes internacionales.

Leer artículo completo en www.seedcapitalbizkaia.com